AI Article Synopsis
- A vaccine using modified vaccinia Ankara (MVA) to deliver rhesus cytomegalovirus (RhCMV) antigens pp65-2, gB, and IE1 was tested in rhesus macaques, with some having received prior priming with plasmids.
- After two MVA treatments, both vaccinated groups exhibited similar levels of antibody responses and specific cellular immune responses against the antigens.
- The study found comparable reductions in plasma viral loads between vaccinated groups and untreated controls, highlighting the potential of rMVA-based vaccines for CMV and suggesting the need for further research to enhance their effectiveness.
Article Abstract
A vaccine consisting of rhesus cytomegalovirus (RhCMV) pp65-2, gB and IE1 expressed via modified vaccinia Ankara (MVA) was evaluated in rhesus macaques with or without prior priming with expression plasmids for the same antigens. Following two MVA treatments, comparable levels of anti-gB, pp65-2 and neutralizing antibody responses, and pp65-2- and IE1-specific cellular immune responses were detected in both vaccinated groups. Similar reductions in plasma peak viral loads were observed in these groups compared to untreated controls. This study demonstrates the immunogenicity and protective efficacy of rMVA-based RhCMV subunit vaccines in a primate host and warrants further investigation to improve the efficacy of subunit vaccines against CMV.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00430-008-0074-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!